Live signal feed

The chain others read separately, joined in time.

NIH grant → clinical trial → public-company event. We snapshot all three daily and surface the upstream move before the downstream one is news. Last snapshot 2026-08-05 · 40 signals · 80 grants, 152 trials, 10398 tickers indexed.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingNVO55% conf

NOVO NORDISK A S (NVO) — PHASE1 primary completion in ~143 days

Upstream (observed)
Clinical trial status (PHASE1) — A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingAZN55% conf

ASTRAZENECA PLC (AZN) — PHASE1 primary completion in ~105 days

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingAZN55% conf

ASTRAZENECA PLC (AZN) — trial primary completion in ~57 days

Upstream (observed)
Clinical trial status (n/a) — A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Trial → FilingAZN55% conf

ASTRAZENECA PLC (AZN) — PHASE1 primary completion in ~177 days

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — trial protocol updated 1 days ago

Upstream (observed)
Clinical trial status (n/a) — Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Trial → FilingIMNN35% conf

Imunon, Inc. (IMNN) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingGMAB35% conf

GENMAB A/S (GMAB) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — trial protocol updated 1 days ago

Upstream (observed)
Clinical trial status (n/a) — A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 2 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 7 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingMPLT35% conf

MapLight Therapeutics, Inc. (MPLT) — PHASE2 protocol updated 7 days ago

Upstream (observed)
Clinical trial status (PHASE2) — An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingMPLT35% conf

MapLight Therapeutics, Inc. (MPLT) — PHASE2 protocol updated 7 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 8 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingACAD35% conf

ACADIA PHARMACEUTICALS INC (ACAD) — PHASE3 protocol updated 12 days ago

Upstream (observed)
Clinical trial status (PHASE3) — ACP-204 in Adults With Alzheimer's Disease Psychosis

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 1 days ago

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE1 protocol updated 2 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingPODD35% conf

INSULET CORP (PODD) — trial protocol updated 2 days ago

Upstream (observed)
Clinical trial status (n/a) — French Prospective Multicentric Study in Real World

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Area heat50% conf

"obesity" heating up — 0 grants ($0), 34 active trials (17 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Area heat50% conf

"Alzheimer" heating up — 7 grants ($201,663,621), 36 active trials (15 started <12 mo)

Upstream (observed)
NIH grant velocity — 7 grants, $201,663,621 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Grant → Trial42% conf

NIH-funded research entered the clinic: "Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer"

Upstream (observed)
NIH RePORTER grant — NATIONAL CANCER INSTITUTE — Biomedical Information Technology, Software Development, and Informatics Support (FY2025, $30,861,067) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compa…"

Upstream (observed)
NIH RePORTER grant — NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES — NIAID CCMF allocation (FY2025, $118,430,841) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantat…"

Upstream (observed)
NIH RePORTER grant — NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES — NIAID CCMF allocation (FY2025, $118,430,841) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Gestational Response, Outcomes, and Weight After GLP-1 Use"

Upstream (observed)
NIH RePORTER grant — VANDERBILT UNIVERSITY MEDICAL CENTER — All of Us Research Program Data and Research Center (FY2025, $40,678,454) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "HealthyTogether: RCT of a Dyadic Weight Management Intervention"

Upstream (observed)
NIH RePORTER grant — PPD DEVELOPMENT LP — NIAID Division of AIDS (DAIDS) Clinical Site Monitoring (FY2026, $25,151,345) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study"

Upstream (observed)
NIH RePORTER grant — NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES — NIAID CCMF allocation (FY2025, $118,430,841) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Adapting RDAD for DS"

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial"

Upstream (observed)
NIH RePORTER grant — UNIVERSITY OF MICHIGAN AT ANN ARBOR — Health and Retirement Study: Yrs 35-40 (FY2026, $32,538,512) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Potatoes, Type 2 Diabetes, and Cardiometabolic Health"

Upstream (observed)
NIH RePORTER grant — OHIO STATE UNIVERSITY — Analyses to Reveal Trajectories and Early Markers of Imminent Shifts in Suicida… (FY2025, $19,515,757) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Area heat26% conf

"GLP-1" heating up — 0 grants ($0), 7 active trials (2 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Area heat20% conf

"immunotherapy" heating up — 0 grants ($0), 3 active trials (0 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)